Jiangsu Hengrui Pharmaceuticals (01276): HRS9531 injection receives approval notification for clinical drug trial.

Jiangsu Hengrui Pharmaceuticals (01276) announced that recently, its subsidiary Fujian Shengdi Pharmaceutical Co., Ltd. received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration for HRS9531 injection, and will soon start clinical trials. HRS9531 injection is a new type of dual agonist targeting the gastric inhibitory peptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R), with HRS9531 as the main active ingredient and global independent intellectual property rights. It can regulate glucose and lipid metabolism, suppress appetite, and enhance insulin sensitivity in the body, thereby improving blood sugar levels and reducing weight. For patients with metabolic dysfunction-related non-alcoholic steatohepatitis (NASH), HRS9531 injection is expected to bring comprehensive benefits through improving liver lipid accumulation, reducing inflammation, and potentially improving liver fibrosis. Currently, there are no similar drugs approved for NASH worldwide.